Eun Ju Choo

ORCID: 0000-0003-2842-7041
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antimicrobial Resistance in Staphylococcus
  • SARS-CoV-2 and COVID-19 Research
  • Pneumonia and Respiratory Infections
  • Antibiotic Resistance in Bacteria
  • Bacterial Identification and Susceptibility Testing
  • Respiratory viral infections research
  • Influenza Virus Research Studies
  • Infective Endocarditis Diagnosis and Management
  • COVID-19 Clinical Research Studies
  • Streptococcal Infections and Treatments
  • Tuberculosis Research and Epidemiology
  • Infectious Diseases and Tuberculosis
  • Herpesvirus Infections and Treatments
  • Antibiotics Pharmacokinetics and Efficacy
  • Infection Control in Healthcare
  • Orthopedic Infections and Treatments
  • Diagnosis and treatment of tuberculosis
  • Urinary Tract Infections Management
  • Antibiotic Use and Resistance
  • Viral gastroenteritis research and epidemiology
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Bacterial Infections and Vaccines
  • Fungal Infections and Studies
  • Mycobacterium research and diagnosis
  • Hepatitis Viruses Studies and Epidemiology

Bucheon University
2015-2025

Soonchunhyang University
2015-2025

Chung-Ang University
2025

Soonchunhyang University Hospital
2006-2017

San Francisco General Hospital
2016-2017

University of California, San Francisco
2016

University of Ulsan
2002-2009

Ulsan College
2003-2009

Asan Medical Center
2003-2007

There is limited information about the clinical course and viral load in asymptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).To quantitatively describe SARS-CoV-2 molecular shedding symptomatic patients.A retrospective evaluation was conducted for a cohort of 303 infection between March 6 26, 2020. Participants were isolated community treatment center Cheonan, Republic Korea.Epidemiologic, demographic, laboratory data collected analyzed. Attending...

10.1001/jamainternmed.2020.3862 article EN JAMA Internal Medicine 2020-08-06
Ana Strezova Javier Díez‐Domingo Kamal Al Shawafi Juan Carlos Tinoco Meng Shi and 95 more Paola Pirrotta Agnes Mwakingwe-Omari Michael A. Adams Anitta Ahonen Charles P. Andrews Eugene Athan Jose-Fernando Barba-Gómez Piero Barbanti Elisabeth Barberan Alain Baty Niklas Bengtsson Juergen Berger-Roscher Katarina Berndtsson Blom Jean Beytout Loïc Boucher Céline Boutry Alain Boye François Brault Laurie Breger Carles Brotons Cuixart Covadonga Caso Christine Cerna Huey‐Shinn Cheng Hee Jin Cheong Eun Ju Choo Clóvis Cunha Anthony L. Cunningham Dan Curiac Benoit Daguzan Antje Dahmen Susan Datta Maria Giuseppina Desole Emmanuel Di Paolo Marc Dionne Petr Dítě Jan Dutz John Earl Tamara Eckermann William Ellison Jurij Eremenko Meral Esen Takashi Eto Xavier Farrés Fabré Cecil Farrington Murdo Ferguson Pierre André Ferrand Matthew Finneran David Francyk Marshall Freedman George Freeman Antônio Tarcísio Freire Péter Gál Jean-Sebastien Gauthier Beatrice Gerlach Wayne Ghesquière Iris Gorfinkel Christine Grigat Josef Großkopf Mónika Inés Hamann Pascal Hanrion Paul Hartley Andrew Hastie Ken Heaton Agnes Himpel-Boenninghoff Thomas Horacek David S.C. Hui Yieng Huong Shinn‐Jang Hwang Giancarlo Icardi Gabriele Illies Junya Irimajiri Jacob Wilson Alen Jambrecina Thiago Junqueira Avelino‐Silva George Kalema Hyo Youl Kim Christiane Klein Uwe Kleinecke Hans-Joachim Koenig Satu Kokko Pavel Kosina Susanna Koski Pekka Koskinen Maximilian Kropp Rie Kuroki Outi Laajalahti Pierre Lachance Jacob Lee Jin Soo Lee Peter Levins Robert Lipetz Bo Liu Chiu-Shong Liu Martin Lundvall Luci Magimaiseelan

Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study ZOE-50/70 trials demonstrated that efficacy against herpes remained high. Moreover, safety profile clinically acceptable, suggesting clinical benefit RZV in ≥50-year-olds is sustained up to years.

10.1093/ofid/ofac485 article EN Open Forum Infectious Diseases 2022-10-01
Michael G. Ison Alberto Papi Eugene Athan Robert G. Feldman Joanne M. Langley and 95 more Dong‐Gun Lee Isabel Leroux‐Roels Federico Martinón‐Torres Tino F. Schwarz Richard N. van Zyl-Smit Céline Verheust Nancy Dezutter Olivier Gruselle Laurence Fissette Marie‐Pierre David Lusiné Kostanyan Veronica Hulstrøm Aurélie Olivier Marie Van der Wielen Dominique Descamps Mark N. Adams Michael L. Adams Clara Agutu Elaine Jacqueline Akité Ingrid Alt Charles P. Andrews Rafaelle Antonelli-Incalzi Asmik Asatryan Ghazaleh Bahrami Elena Bargagli Qasim Bhorat Paul Bird Przemysław Borowy Céline Boutry Carles Brotons Cuixart David A. Browder Judith C. Brown Erik Buntinx Donald P. Cameron Laura Cámpora Cyrille Cartier Kenneth Chinsky Melissa Choi Eun Ju Choo Delphine Collete Maria Corral Carrillo Susanna Cuadripani Matthew Davis Magali de Heusch Ferdinandus de Looze Marc De Meulemeester Ferdinando De Negri Nathalie De Schrevel David DeAtkine Viktoriya Dedkova Peter Dzongowski Tamara Eckermann Brandon Essink Karen Faulkner Murdo Ferguson Gregory N. Fuller Isabel Maria Galan Melendez Ivan Gentile Wayne Ghesquière Doria Grimard Scott A. Halperin Amardeep Heer Laura Helman Andre Hotermans Tomáš Jelı́nek Jackie Kamerbeek Hyo Youl Kim Murray Kimmel Mark Koch Satu Kokko Susanna Koski Shady Kotb Antonio Lalueza Jin Soo Lee Muriel Lins Johannes Lombaard Akbar Mahomed Mario Malerba Céline Maréchal Sandie Marion Jean‐Benoît Martinot Cristina Masuet‐Aumatell Damien McNally Carlos Eduardo Medina Pech J M Gonzalez Galvan Lise Mercati Narcisa Mesaros Dieter Mesotten Essack Mitha Kathryn Mngadi Beate Moeckesch Barnaby Montgomery Linda Murray Rhiannon Nally Silvia Narejos Pérez

Abstract Background The adjuvanted RSV prefusion F protein–based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 season. We evaluated efficacy and safety of RSVPreF3 OA dose 2 doses given year apart RSV-LRTD seasons post–dose 1. Methods In this phase 3, blinded trial, ≥60-year-olds were randomized (1:1) to receive or placebo pre–season recipients re-randomized a second (RSV_revaccination group) (RSV_1dose 2;...

10.1093/cid/ciae010 article EN cc-by Clinical Infectious Diseases 2024-01-22
Céline Boutry Andrew Hastie Javier Díez‐Domingo Juan Carlos Tinoco Chong‐Jen Yu and 95 more Charles P. Andrews Jean Beytout Covadonga Caso Huey‐Shinn Cheng Hee Jin Cheong Eun Ju Choo Dan Curiac Emmanuel Di Paolo Marc Dionne Tamara Eckermann Meral Esen Murdo Ferguson Wayne Ghesquière Shinn‐Jang Hwang Thiago Junqueira Avelino‐Silva Pavel Kosina Chiu-Shong Liu Jukka Markkula Beate Moeckesch Cláudia Murta de Oliveira Dae Won Park Karlis Pauksens Paola Pirrotta Georg Plassmann Carol Pretswell Lars Rombo Bruno Salaun Johan Berglund Isabelle Schenkenberger Tino F. Schwarz Meng Shi Benita Ukkonen Toufik Zahaf Cristiano A. F. Zerbini Anne Schuind Anthony L. Cunningham Michael A. Adams Anitta Ahonen Eugene Athan Jose-Fernando Barba-Gómez Piero Barbanti Elisabeth Barberan Alain Baty Niklas Bengtsson Juergen Berger-Roscher Katarina Berndtsson Blom Loïc Boucher Alain Boye François Brault Laurie Breger Carles Brotons Cuixart Christine Cerna Clóvis Cunha Benoit Daguzan Antje Dahmen Susan Datta Maria Giuseppina Desole Petr Dítě Jan Dutz John Earl William Ellison Jurij Eremenko Takashi Eto Xavier Farrés Fabré Cecil Farrington Pierre André Ferrand Matthew Finneran David Francyk Marshall Freedman George Freeman Péter Gál Jean-Sebastien Gauthier Beatrice Gerlach Iris Gorfinkel Christine Grigat Josef Großkopf Mónika Inés Hamann Pascal Hanrion Paul Hartley Ken Heaton Agnes Himpel-Boenninghoff Thomas Horacek David S.C. Hui Yieng Huong Giancarlo Icardi Gabriele Illies Junya Irimajiri Alen Jambrecina Hyo Youl Kim Christiane Klein Uwe Kleinecke Hans-Joachim Koenig Satu Kokko Pekka Koskinen Maximilian Kropp

Abstract Background This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age ≥50 2 pivotal trials (ZOE-50 ZOE-70). The present interim analysis was performed after ≥2 (between 5.1 7.1 [mean] post-vaccination) includes partial data year (Y) 8 post-vaccination. Methods Annual assessments were against herpes (HZ) from Y6 post-vaccination...

10.1093/cid/ciab629 article EN cc-by Clinical Infectious Diseases 2021-07-20
Robert G. Feldman Raffaele Antonelli Incalzi Katie Steenackers Dong‐Gun Lee Alberto Papi and 95 more Michael G. Ison Laurence Fissette Marie‐Pierre David Céline Maréchal Marie Van der Wielen Lusiné Kostanyan Veronica Hulstrøm Mark Adams Michael L. Adams Elaine Jacqueline Akité Ingrid Alt Charles P. Andrews Asmik Asatryan Eugene Athan Ghazaleh Bahrami Elena Bargagli Qasim Bhorat Paul Bird Przemysław Borowy Céline Boutry Carles Brotons Cuixart David A. Browder Judith C. Brown Erik Buntinx Donald P. Cameron Laura Cámpora Kenneth Chinsky Melissa Choi Eun Ju Choo Delphine Collete Maria Corral Carrillo Matthew Davis Magali de Heusch Ferdinandus de Looze Marc De Meulemeester Ferdinando De Negri Nathalie De Schrevel David DeAtkine Viktoriya Dedkova Dominique Descamps Nancy Dezutter Peter Dzongowski Tamara Eckermann Brandon Essink Karen Faulkner Murdo Ferguson Gregory N. Fuller Isabel Maria Galan Melendez Ivan Gentile Wayne Ghesquière Doria Grimard Olivier Gruselle Scott A. Halperin Amardeep Heer Laura Helman Andre Hotermans Tomáš Jelı́nek Jackie M Kamerbeek Hyo Youl Kim Murray Kimmel Mark Koch Satu Kokko Susanna Koski Shady Kotb Antonio Lalueza Joanne M. Langley Jin Soo Lee Isabel Leroux‐Roels Muriel Lins Johannes Lombaard Akbar Mahomed Mario Malerba Céline Maréchal Federico Martinón‐Torres Jean‐Benoît Martinot Cristina Masuet‐Aumatell Damien McNally Carlos Eduardo Medina Pech J M Gonzalez Galvan Narcisa Mesaros Dieter Mesotten Essack Mitha Kathryn Mngadi Beate Moeckesch Barnaby Montgomery Linda Murray Rhiannon Nally Silvia Narejos Pérez Joseph Newberg Paul Nugent Dolores Ochoa Mazarro Harunori Oda Aurélie Olivier Maurizio Orso Jacinto Ortiz Molina

Abstract Background Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute illness (RSV-ARI) and severe disease. In an ongoing, randomized, placebo-controlled, multicountry, phase 3 trial in ≥60-year-old participants, AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower tract disease (RSV-LRTD), RSV-LRTD, RSV-ARI. We evaluated efficacy...

10.1093/cid/ciad471 article EN cc-by Clinical Infectious Diseases 2023-09-12

The isolation of carbapenem-resistant Klebsiella pneumoniae (CRKP) has been increasingly reported. However, no study analyzing potential risk factors for the acquisition CRKP published as now. We therefore performed a case-control to determine CRKP. was nosocomially isolated from 30 patients between January 1997 and August 2003. Control were randomly selected at ratio 4:1 same medical or surgical services which receiving care when occurred. Risk previous use carbapenem (adjusted odds [AOR],...

10.1089/mdr.2005.11.165 article EN Microbial Drug Resistance 2005-05-23

ABSTRACT Penicillin-binding protein 4 (PBP4), a nonessential, low-molecular-weight penicillin-binding of Staphylococcus aureus , has been implicated in low-level resistance to β-lactam antibiotics, although the mechanism is unknown. Mutations PBP4 and its promoter were identified laboratory-generated mutant strain, CRB, which expresses high-level β-lactams, including new-generation cephalosporins active against methicillin-resistant strains S. . These mutations did not appreciably alter...

10.1128/aac.02727-16 article EN Antimicrobial Agents and Chemotherapy 2017-04-04

Abstract Background Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle that displays SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes. Methods Initial study phase 2 randomized, observer-blind, placebo-controlled trial assess immunogenicity, safety, and tolerance ECV19 was carried out between July October 2021. Two hundred twenty-nine participants were enrolled at...

10.1186/s12916-022-02661-1 article EN cc-by BMC Medicine 2022-11-30

The Korean Society of Infectious Diseases has been regularly developing guidelines for adult immunization since 2007. In 2023, the following seven vaccines were revised: influenza, herpes zoster, pneumococcal, tetanus-diphtheria-pertussis (Tdap), human papillomavirus (HPV), meningococcal, and rabies vaccines. For influenza vaccine, a recommendation enhanced elderly was added. zoster recombinant vaccine pneumococcal current status 15-valent conjugate 20-valent PCV described. Tdap possibility...

10.3947/ic.2023.0072 article EN cc-by-nc Infection and Chemotherapy 2024-01-01

The nephrotoxicity of colistin has been reported in the literature. A previous report shown that acute kidney injury (AKI) occurred after an average 13.5 days, but we have experienced AKI developed with administration earlier. We investigated clinical features patients who according to time development use. retrospectively collected data were admitted 4 hospitals between January 2007 and May 2009. This study included 119 had received intravenous for over 72 h. compared early group (AKI...

10.1159/000320746 article EN Nephron Clinical Practice 2010-09-17

We investigated the prevalence of latent tuberculosis infection (LTBI) among health care workers (HCWs) and analyzed its risk factors in South Korea.A standard questionnaire regarding baseline demographics for LTBI was given to each participant tuberculin skin test (TST), QuantiFERON-TB GOLD In-Tube (QFT-GIT) assay, chest radiography were performed.A total 493 participants, 152 (30.8%) doctors 341 (69.2%) nurses enrolled eight tertiary referral hospitals. The mean age subjects 30.6 years...

10.4046/trd.2013.75.1.18 article EN cc-by-nc Tuberculosis & respiratory diseases 2013-01-01

Acinetobacter baumannii, an opportunistic nosocomial pathogen that can cause significant morbidity and mortality, has emerged as a worldwide problem. The aim of this study was to evaluate the risk factors for mortality in patients with A. baumannii bacteremia. We retrospectively evaluated 118 who had bacteremia between July 2003 December 2011. identify 30-day relevant factors. bacteremia-related rate 34.1%. Univariate analysis revealed included malignancy, longer hospital stay before...

10.3947/ic.2013.45.3.325 article EN cc-by-nc Infection and Chemotherapy 2013-01-01

•Multi-drug resistant organisms (MDRO) were isolated from 8.6% of COVID-19 pneumonia.•MDROs detected 28% (13/47) among patients with culture data.•Long-term care facility stay was a risk factor for isolation organisms.•Corticosteroids use in may increase the bacterial co-infection.•Strict infection prevention strategies be needed factors. ObjectivesSuperimposed multi-drug (MDROs) co-infection can associated worse outcomes severe coronavirus disease 2019 (COVID-19), even if these managed...

10.1016/j.ajic.2021.06.005 article EN other-oa American Journal of Infection Control 2021-06-17

EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective this study was to determine the longer-term antibody response vaccine.To assess immunogenicity 6 and 12 months vaccination, participants in (NCT04783311) were excluded if they: 1) withdrew, 2) infection or additional 3) exhibited increasing...

10.1016/j.ijid.2023.11.004 article EN cc-by International Journal of Infectious Diseases 2023-11-07

The clinical significance and virulence potential of Enterococcus casseliflavus/flavescens gallinarum are still uncertain. We retrospectively analyzed 56 cases significant bacteremia caused by E. casseliflavus or gallinarum. Of these cases, 25 (44.6%) were associated with polymicrobial bacteremia, 43 (76.8%) entry via the biliary tract. Resistance to vancomycin was observed in 17 (30.4%) patients, this resistance significantly (adjusted odds ratio [AOR], 10.56; 95% confidence interval [CI],...

10.1086/380452 article EN Clinical Infectious Diseases 2003-12-18

Objectives: We investigated the trends of nalidixic acid resistance in human non-typhoid Salmonella enterica a Korean population, and examined some possible mechanisms involved this resistance.

10.1093/jac/dki369 article EN Journal of Antimicrobial Chemotherapy 2005-10-21

We estimated the nationwide burden of nosocomial S. aureus bloodstream infection (SA-BSI), a major cause infection, in South Korea. To evaluate incidence SA-BSI, cases SA-BSI were prospectively collected from 22 hospitals with over 500 beds 4?months. Data on patient-days obtained national health insurance database containing claims data for all healthcare facilities The additional cost was through matched case?control study. economic calculated sum medical costs, costs caregiving and loss...

10.1186/s12879-014-0590-4 article EN cc-by BMC Infectious Diseases 2014-11-14

Abstract Spinal implant infection is a rare but significant complication of spinal fusion surgery, and the most common pathogen Staphylococcus aureus . It difficult to treat due this pathogen's biofilm-forming ability antibiotic resistance. We evaluated therapeutic outcome treatments for S infections. retrospectively reviewed all patients with infections at 11 tertiary-care hospitals over 9-year period. Parameters predictive treatment failure recurrence were analyzed by Cox regression. Of...

10.1097/md.0000000000012629 article EN cc-by-nc Medicine 2018-10-01

In South Korea, the increasing incidence of herpes zoster (HZ) and aging population warrant consideration HZ vaccination for older adults. There is a need to understand vaccine-related preferences adults aged ≥50 years adult children (working or financially independent contributing healthcare decision-making their parents years). A discrete choice experiment was conducted elicit vaccine HZ-naïve general public (n = 500), current/former patients 150), 150). An online questionnaire...

10.1080/21645515.2025.2469419 article EN cc-by-nc Human Vaccines & Immunotherapeutics 2025-03-10
Coming Soon ...